485 related articles for article (PubMed ID: 26279026)
21. Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.
Chao HH; Berman AT; Simone CB; Ciunci C; Gabriel P; Lin H; Both S; Langer C; Lelionis K; Rengan R; Hahn SM; Prabhu K; Fagundes M; Hartsell W; Mick R; Plastaras JP
J Thorac Oncol; 2017 Feb; 12(2):281-292. PubMed ID: 27826034
[TBL] [Abstract][Full Text] [Related]
22. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
23. A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer.
Cagney DN; Thirion PG; Dunne MT; Fleming C; Fitzpatrick D; O'Shea CM; Finn MA; O'Sullivan S; Booth C; Collins CD; Buckney SJ; Shannon A; Armstrong JG
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):30-38. PubMed ID: 29097074
[TBL] [Abstract][Full Text] [Related]
24. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
25. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
[TBL] [Abstract][Full Text] [Related]
26. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
[TBL] [Abstract][Full Text] [Related]
27. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
[TBL] [Abstract][Full Text] [Related]
28. A Phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer: WJTOG 3305.
Tada T; Chiba Y; Tsujino K; Fukuda H; Nishimura Y; Kokubo M; Negoro S; Kudoh S; Fukuoka M; Nakagawa K; Nakanishi Y
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):327-31. PubMed ID: 22079726
[TBL] [Abstract][Full Text] [Related]
29. Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy.
Tada T; Fukuda H; Matsui K; Hirashima T; Hosono M; Takada Y; Inoue Y
Int J Clin Oncol; 2005 Aug; 10(4):247-50. PubMed ID: 16136369
[TBL] [Abstract][Full Text] [Related]
30. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Dilling TJ; Extermann M; Kim J; Thompson LM; Yue B; Stevens CW; Antonia S; Gray J; Williams C; Haura E; Pinder-Schenck M; Tanvetyanon T; Kim S; Chiappori A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):828-33. PubMed ID: 25216856
[TBL] [Abstract][Full Text] [Related]
32. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
[TBL] [Abstract][Full Text] [Related]
33. Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?
de Dios NR; Sanz X; Foro P; Membrive I; Reig A; Ortiz A; Jiménez R; Algara M
Clin Transl Oncol; 2017 Apr; 19(4):440-447. PubMed ID: 27553602
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Jain AK; Hughes RS; Sandler AB; Dowlati A; Schwartzberg LS; Dobbs T; Schlabach L; Wu J; Muldowney NJ; Choy H
J Thorac Oncol; 2009 Jun; 4(6):722-7. PubMed ID: 19404213
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
Hata M; Tokuuye K; Kagei K; Sugahara S; Nakayama H; Fukumitsu N; Hashimoto T; Mizumoto M; Ohara K; Akine Y
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):786-93. PubMed ID: 17379439
[TBL] [Abstract][Full Text] [Related]
37. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy for lung cancer: target splitting by asymmetric collimation enables reduction of radiation doses to normal tissues and dose escalation.
Wurstbauer K; Deutschmann H; Kranzinger M; Merz F; Rahim H; Sedlmayer F; Kogelnik HD
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):333-41. PubMed ID: 10760428
[TBL] [Abstract][Full Text] [Related]
39. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
[TBL] [Abstract][Full Text] [Related]
40. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
